EPZ5676: Potent and Selective DOT1L Inhibitor for MLL-Rearranged Leukemia

Executive Summary: EPZ5676 is a highly selective DOT1L inhibitor with an IC₅₀ of 0.8 nM and a Ki of 80 pM, offering >37,000-fold selectivity over other methyltransferases (APExBIO); it functions as a SAM-competitive inhibitor, inducing conformational changes in the DOT1L active site. EPZ5676 has demonstrated complete tumor regression in MV4-11 xenograft models of MLL-rearranged leukemia without notable toxicity (Liu et al., 2019). It inhibits H3K79 methylation, downregulates MLL-fusion gene targets, and displays nanomolar antiproliferative activity in vitro. The compound’s solid form supports high solubility in DMSO and ethanol but is insoluble in water. DOT1L inhibition by EPZ5676 is also implicated in mitigating renal fibrosis, illustrating its potential beyond oncology (PMC8793787).

Biological Rationale

DOT1L (disruptor of telomeric silencing-1-like) is the sole enzyme that methylates histone H3 at lysine 79 (H3K79), a key epigenetic modification regulating gene expression in normal and malignant hematopoietic cells (Liu et al., 2019). Aberrant H3K79 methylation is directly linked to oncogenic transformation in mixed lineage leukemia (MLL)-rearranged leukemias. In these leukemias, MLL fusion proteins aberrantly recruit DOT1L to target genes, resulting in sustained H3K79 methylation and leukemogenic gene expression (GTP-Solution 2021). Inhibition of DOT1L disrupts this pathway, highlighting DOT1L as a validated therapeutic target in MLL-driven cancers. Recent research also implicates DOT1L in fibrotic diseases, such as chronic kidney disease, where its activity is associated with fibroblast activation and epithelial-mesenchymal transition (Liu et al., 2019).

Mechanism of Action of DOT1L inhibitor EPZ-5676

EPZ5676 is a SAM-competitive small-molecule inhibitor that binds to the S-adenosyl methionine pocket of DOT1L, inducing conformational changes that open a hydrophobic pocket beyond the amino acid portion of SAM (APExBIO). This binding mechanism confers high specificity, resulting in an IC₅₀ of 0.8 nM and a Ki of 80 pM for DOT1L (Liu et al., 2019). EPZ5676 does not significantly inhibit other methyltransferases, including CARM1, EHMT1/2, EZH1/2, PRMTs, SETD7, SMYD2/3, or WHSC1/1L1, even at concentrations >37,000-fold higher than required for DOT1L inhibition (APExBIO). Inhibition of DOT1L by EPZ5676 blocks H3K79 methylation, leading to reduced expression of leukemogenic genes and potent cytotoxicity in acute leukemia cells with MLL translocations. In non-oncogenic contexts, such as renal fibrosis, EPZ5676 blocks fibroblast activation and epithelial-mesenchymal transition via DOT1L inhibition (Liu et al., 2019).

Evidence & Benchmarks

• EPZ5676 exhibits >37,000-fold selectivity for DOT1L over other methyltransferases, as determined by enzyme inhibition assays (see Table 1 in APExBIO).
• MV4-11 acute leukemia cells treated with EPZ5676 display a proliferation IC₅₀ of 3.5 nM after 4–7 days of exposure (APExBIO).
• In vivo, nude rats with MV4-11 xenografts achieved complete tumor regression with EPZ5676 dosed at 35–70 mg/kg/day (IV, 21 days), with no significant toxicity or weight loss (Liu et al., 2019).
• EPZ5676 administration in a murine renal fibrosis model attenuated fibroblast activation and epithelial-mesenchymal transition, indicating efficacy beyond leukemia (see Figure 3, doi:10.1096/fj.201801861R).
• DOT1L inhibition by EPZ5676 lowers H3K79 methylation and downregulates MLL-fusion gene targets (e.g., HOXA9, MEIS1) in cell-based assays (Carmofur.com).

This article extends the evidence-driven guidance in "DOT1L inhibitor EPZ-5676 (SKU A4166): Data-Backed Solution" by including recent data on antifibrotic activity and providing a detailed mechanistic rationale for selectivity. For a broader overview of epigenetic workflows, see "EPZ5676: Potent DOT1L Inhibitor for Precision Leukemia Research", which this article updates with new in vivo findings.

Applications, Limits & Misconceptions

EPZ5676 is primarily used in biochemical assays for DOT1L inhibition, cell proliferation/cytotoxicity studies, and in vivo models of MLL-rearranged leukemia. Its unique selectivity profile facilitates the study of H3K79 methylation in both cancer and fibrotic disease models. The compound is particularly suited for dissecting the role of epigenetic regulation in leukemia and renal fibrosis (Liu et al., 2019).

Common Pitfalls or Misconceptions

• EPZ5676 is not effective against non-DOT1L-dependent cancers; tumors lacking MLL rearrangements may not respond.
• The compound is insoluble in water and requires DMSO or ethanol (with sonication) for dissolution; improper solubilization can lead to assay artifacts (APExBIO).
• Long-term storage of solutions (especially above -20°C) or repeated freeze-thaw cycles can degrade potency.
• DOT1L inhibition does not affect all histone methylation marks; EPZ5676 does not inhibit EZH2, G9a, or PRMT family methyltransferases (APExBIO).
• In vivo antifibrotic effects are specific to models with DOT1L upregulation, such as renal injury; effects may not generalize to all fibrotic conditions.

Workflow Integration & Parameters

For in vitro assays, EPZ5676 should be dissolved in DMSO (≥28.15 mg/mL) or ethanol (≥50.3 mg/mL with ultrasonic assistance), ensuring complete solubilization. Stock solutions are stable at -20°C for several months. For cell-based assays, typical concentrations range from 1–100 nM, with exposure times of 4–7 days for optimal antiproliferative readout in MLL-rearranged leukemia lines such as MV4-11. For in vivo studies, dosing regimens of 35–70 mg/kg/day intravenously for 21 days have been validated in xenograft models. Monitoring animal weight and health is essential to confirm absence of toxicity (Liu et al., 2019).

For detailed guidance on assay optimization, consult "DOT1L inhibitor EPZ-5676 (SKU A4166): Data-Backed Solution", which this article builds upon by providing updated mechanistic and antifibrotic evidence.

Conclusion & Outlook

EPZ5676, as offered by APExBIO, represents a gold-standard tool for selective inhibition of DOT1L in both oncology and emerging fibrotic disease applications. Its unmatched potency, selectivity, and favorable in vivo profile enable rigorous investigation into H3K79 methylation and epigenetic regulation in cancer. Ongoing research into DOT1L’s broader role in tissue fibrosis and other diseases may expand the utility of EPZ5676 beyond hematologic malignancies (Liu et al., 2019). Continued benchmarking, proper workflow integration, and attention to solubility and storage parameters will ensure optimal results in both basic and translational research.